MX2021005438A - Metodos para reducir el tama?o de tumores hipofisarios. - Google Patents
Metodos para reducir el tama?o de tumores hipofisarios.Info
- Publication number
- MX2021005438A MX2021005438A MX2021005438A MX2021005438A MX2021005438A MX 2021005438 A MX2021005438 A MX 2021005438A MX 2021005438 A MX2021005438 A MX 2021005438A MX 2021005438 A MX2021005438 A MX 2021005438A MX 2021005438 A MX2021005438 A MX 2021005438A
- Authority
- MX
- Mexico
- Prior art keywords
- relacorilant
- pituitary
- tumors
- hormone
- treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Los tumores hipofisarios se pueden reducir en tamaño mediante la administración de relacorilante. Las neoplasias hipofisarias incluyen, entre otras, tumores no secretores, tumores secretores hormonales, adenomas y carcinomas. La administración de relacorilante puede ser eficaz para reducir la secreción hormonal de un tumor hipofisario que segregue hormonas, por ejemplo, para reducir la secreción de hormona adrenocorticotrófica (ACTH). Se puede obtener una imagen de un tumor hipofisario antes y/o después de ser administrable el relacorilante. El relacorilante puede ser administrable indistintamente de la cirugía, y antes, durante o después de la cirugía para tratar un tumor hipofisario. El relacorilante puede ayudar o mejorar los resultados quirúrgicos y puede reducir el tamaño o el crecimiento del tejido tumoral hipofisario antes de la cirugía y cualquier tejido tumoral restante después del tratamiento quirúrgico. El relacorilante puede ser administrable por vía oral para el tratamiento contra neoplasias hipofisarias. El relacorilante puede ser administrable por vía oral a un paciente en ayunas o a un paciente alimentado. El relacorilante puede ser administrable junto con otros tratamientos con acción selectiva al tumor hipofisario, incluidos los tratamientos quirúrgicos, los tratamientos de radiación, la quimioterapia para carcinomas y otros tratamientos farmacéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758477P | 2018-11-09 | 2018-11-09 | |
| PCT/US2019/060548 WO2020097513A1 (en) | 2018-11-09 | 2019-11-08 | Methods for shrinking pituitary tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005438A true MX2021005438A (es) | 2021-06-15 |
Family
ID=70551489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005438A MX2021005438A (es) | 2018-11-09 | 2019-11-08 | Metodos para reducir el tama?o de tumores hipofisarios. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10946005B2 (es) |
| EP (1) | EP3876936A4 (es) |
| JP (1) | JP7159470B2 (es) |
| KR (1) | KR102651146B1 (es) |
| CN (1) | CN113015528A (es) |
| AU (1) | AU2019377864B2 (es) |
| BR (1) | BR112021008719A2 (es) |
| CA (1) | CA3117058C (es) |
| IL (1) | IL283043A (es) |
| MX (1) | MX2021005438A (es) |
| PH (1) | PH12021551023A1 (es) |
| SG (1) | SG11202104732UA (es) |
| UA (1) | UA125365C2 (es) |
| WO (1) | WO2020097513A1 (es) |
| ZA (1) | ZA202102652B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210107004A (ko) * | 2018-12-20 | 2021-08-31 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 소마토스타틴 수용체 양성 종양의 영상화 및 치료 방법 |
| AU2020355094A1 (en) * | 2019-09-24 | 2022-04-14 | The Board Of Regents Of The University Of Texas System | Methods and systems for analyzing brain lesions with longitudinal 3D MRI data |
| EP4157274A1 (en) * | 2020-05-27 | 2023-04-05 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates |
| CN115697337A (zh) * | 2020-05-27 | 2023-02-03 | 科赛普特治疗学股份有限公司 | 糖皮质激素受体调节剂瑞拉可兰和紫杉醇(cyp2c8和cyp3a4的双重底物)的并行给药 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PL2854814T3 (pl) * | 2012-05-25 | 2018-07-31 | Corcept Therapeutics, Inc. | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| AU2016226451B2 (en) | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| WO2017151613A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
-
2019
- 2019-11-08 JP JP2021525281A patent/JP7159470B2/ja active Active
- 2019-11-08 EP EP19881977.3A patent/EP3876936A4/en active Pending
- 2019-11-08 AU AU2019377864A patent/AU2019377864B2/en active Active
- 2019-11-08 BR BR112021008719-2A patent/BR112021008719A2/pt unknown
- 2019-11-08 WO PCT/US2019/060548 patent/WO2020097513A1/en unknown
- 2019-11-08 CA CA3117058A patent/CA3117058C/en active Active
- 2019-11-08 KR KR1020217016943A patent/KR102651146B1/ko active IP Right Grant
- 2019-11-08 MX MX2021005438A patent/MX2021005438A/es unknown
- 2019-11-08 UA UAA202103152A patent/UA125365C2/uk unknown
- 2019-11-08 SG SG11202104732UA patent/SG11202104732UA/en unknown
- 2019-11-08 CN CN201980073411.4A patent/CN113015528A/zh active Pending
- 2019-11-08 US US16/678,988 patent/US10946005B2/en active Active
-
2021
- 2021-02-25 US US17/185,133 patent/US20210177817A1/en active Pending
- 2021-04-21 ZA ZA2021/02652A patent/ZA202102652B/en unknown
- 2021-05-04 PH PH12021551023A patent/PH12021551023A1/en unknown
- 2021-05-09 IL IL283043A patent/IL283043A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102651146B1 (ko) | 2024-03-25 |
| ZA202102652B (en) | 2022-09-28 |
| CA3117058C (en) | 2024-02-13 |
| SG11202104732UA (en) | 2021-06-29 |
| US20200147065A1 (en) | 2020-05-14 |
| IL283043A (en) | 2021-06-30 |
| JP2022509051A (ja) | 2022-01-20 |
| KR20210076149A (ko) | 2021-06-23 |
| CN113015528A (zh) | 2021-06-22 |
| AU2019377864A1 (en) | 2021-06-03 |
| EP3876936A1 (en) | 2021-09-15 |
| PH12021551023A1 (en) | 2022-02-21 |
| WO2020097513A1 (en) | 2020-05-14 |
| US10946005B2 (en) | 2021-03-16 |
| AU2019377864B2 (en) | 2023-03-16 |
| CA3117058A1 (en) | 2020-05-14 |
| US20210177817A1 (en) | 2021-06-17 |
| JP7159470B2 (ja) | 2022-10-24 |
| EP3876936A4 (en) | 2022-08-17 |
| UA125365C2 (uk) | 2022-02-23 |
| BR112021008719A2 (pt) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551023A1 (en) | Methods for shrinking pituitary tumors | |
| NZ749192A (en) | Ar+ breast cancer treatment methods | |
| JP2017039771A5 (es) | ||
| MX2020008771A (es) | Agonistas del estimulador de genes interferon. | |
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| MX2019012884A (es) | Terapia de combinacion. | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| Misra et al. | Prevention of PONV by acustimulation with capsicum plaster is comparable to ondansetron after middle ear surgery | |
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| EA202190457A1 (ru) | Конъюгаты для применения в способах лечения рака | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| MX2017014481A (es) | Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la tirosina quinasa. | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
| BR112022000734A2 (pt) | Método para tratar câncer em um paciente, uso de composto 1, e, composto 1 | |
| MX2021000207A (es) | Regímenes de dosificación para el tratamiento de daños en los tejidos asociados a la hipoxia. | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| RU2021110680A (ru) | Комбинированная терапия, включающая соединение ацилтиомочевины и абиратерон |